BRIEF-U.S. FDA panel recommends label change for Takeda's diabetes drug
April 14, 2015 at 16:50 PM EDT
April 14 (Reuters) - An advisory panel to the U.S. Food and Drug Administration voted 13-3 that Takeda Pharmaceutical's diabetes drug Nesina should contain information about a potential increased risk of heart failure.